Identification of novel bioactive glycans on dystroglycan
Identification of novel bioactive glycans on dystroglycan
批准号:
7244131
负责人:
PAUL Taylor MARTIN
金额:
$15.51万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-25 至 2009-04-30
关键词:
BindingCell Adhesion MoleculesCellsChitinChitosanDataDefectDevelopmentDiseaseDoctor of PhilosophyDystroglycanEnzymesExtracellular Matrix ProteinsGenesGlycoproteinsLamininLigand BindingLinkLower OrganismMammalsMannoseMediatingMediationMolecularMusMuscular DystrophiesMutateMutationOligosaccharidesPatientsPhenotypePlayPolysaccharidesProtein OverexpressionProteinsRecombinantsResearch PersonnelRoleStructureTherapeuticbasecarbohydrate structurechitosanasecongenital muscular dystrophyglycosylationglycosyltransferasehuman diseasenovelprogramsprotein O-mannose beta-1,2-N-acetylglucosaminyltransferase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Dystroglycan is a cell adhesion molecule that plays important roles in neuromuscular and cortical development and in muscular dystrophy. The glycosylation of a dystroglycan (aDG) is essential for its function; Six genes have been identified that, when mutated, cause the underglycosylation of aDG leading to diminished or absent binding of extracellular matrix proteins, including laminin. Defects in these genes also cause forms of congenital muscular dystrophy (CMD) where underglycosylation of aDG is causative molecular defect. Several of these genes (POMT1, POMT2, POMGnT1) are known to be glycosyltransferases involved in the synthesis of O-linked mannose structures on the aDG protein. In mammals, O-linked mannose has only been shown to exist on aDG. Thus, these carbohydrate structures are highly specific to this one protein. The functions of the three other known CMD genes that alter aDG glycosylation are unknown, despite intense efforts by numerous investigators. One of these is LARGE, the gene deleted in the myodystrophy (LARGEmyd) mouse. LARGE is important not only because defects in this gene cause human disease, but also because its overexpression has been shown to stimulate glycosylation of aDG and rescue laminin binding in cells from CMD patients. Thus, understanding LARGE function may be a key to the development of therapeutics for multiple forms of CMD as well as to understanding the role of dystroglycan in neuromuscular development. Here we provide evidence that suggests that LARGE synthesizes a novel carbohydrate structure. This structure, like O-mannose, appears to be extremely rare in mammals but common in lower organisms. This proposal will conclusively identify the presence of this carbohydrate structure on dystroglycan, define its role in ligand binding, and define the function of LARGE as the enzyme that creates it. This proposal, therefore, will not only define a novel function for a therapeutically important enzyme, but likely identify a glycan structure not yet described in mammals.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A Method to Produce and Purify Full-Length Recombinant Alpha Dystroglycan: Analysis of N- and O-Linked Monosaccharide Composition in CHO Cells with or without LARGE Overexpression.
一种生产和纯化全长重组α肌营养不良聚糖的方法:分析有或没有大量过度表达的CHO细胞中的N-和O-连接单糖组成。
DOI:
10.1371/currents.md.3756b4a389974dff21c0cf13508d3f7b
发表时间:
2013
期刊:
PLoS currents
影响因子:
--
作者:
[Yoon,JungHae, Xu,Rui, Martin,Paul]
通讯作者:
Martin,Paul
Micro-laminin Gene Therapy for MDC1A
-
批准号:10393047
-
项目类别:
-
资助金额:$16.77万
-
财政年份:2021
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Micro-laminin Gene Therapy for MDC1A
-
批准号:10198254
-
项目类别:
-
资助金额:$20.33万
-
财政年份:2021
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Project 1: Preclinical development of surrogate gene therapy using GALGT2
-
批准号:10017023
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2016
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Development of a novel HIBM2 mouse model and therapy
-
批准号:8808258
-
项目类别:
-
资助金额:$19.73万
-
财政年份:2015
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A myoutube-specific deletion model for sarcopenia
-
批准号:8302840
-
项目类别:
-
资助金额:$19.55万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:8639478
-
项目类别:
-
资助金额:$51.14万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A myoutube-specific deletion model for sarcopenia
-
批准号:8454456
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:9071078
-
项目类别:
-
资助金额:$5.52万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:8449165
-
项目类别:
-
资助金额:$49.57万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:9057366
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:8825418
-
项目类别:
-
资助金额:$52.18万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
A new DMD model with a humanized glycome
-
批准号:8235651
-
项目类别:
-
资助金额:$53.28万
-
财政年份:2012
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Training and Education Core
-
批准号:8032774
-
项目类别:
-
资助金额:$13.8万
-
财政年份:2010
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:7902575
-
项目类别:
-
资助金额:$16.05万
-
财政年份:2009
-
负责人:PAUL Taylor MARTIN
-
依托单位:
CT GalNAc Transferase Gene Theraphy For DMD
-
批准号:7328073
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2007
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:7798563
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2006
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:9116094
-
项目类别:
-
资助金额:$58.33万
-
财政年份:2006
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:7393209
-
项目类别:
-
资助金额:$29.73万
-
财政年份:2006
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:8891366
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2006
-
负责人:PAUL Taylor MARTIN
-
依托单位:
Glycosyltransferase Therapy for Myopathies
-
批准号:7090992
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2006
-
负责人:PAUL Taylor MARTIN
-
依托单位:
海外基金